Head-to-Head drug battle aims to tame Crohn's Flare-Ups
NCT ID NCT07499232
First seen Apr 05, 2026 · Last updated May 08, 2026 · Updated 4 times
Summary
This study tests whether guselkumab works better than risankizumab for people with moderate-to-severe Crohn's disease, a condition that causes long-term gut inflammation. About 530 adults will receive one of the two drugs and be followed for a year. The main goal is to see who achieves deep remission, meaning both symptom relief and healed gut lining.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.